Advantages of Positron Emission Tomography (PET) with Respect to Computed Tomography in the Follow-up of Lymphoma Patients with Abdominal Presentation

References

• Vase. LM, Bierman, PI, Anderson, J.R., et at, (1996) "Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Horig,kin's lymphoma",). Cal. 0/1i-Vi. 14, 2473–7479.
   Google Scholar
• Zinzani. P.L., Monetti, N., Zumpatori, M.. et at, (2001) "Importance of gallium SCM1 restaging for curative treatment of mediastinal lymphomas". Harmalologica 86. 1229–1230.
   Google Scholar
• Leskinen-Kalil°. S.. Minn, H. and Joensuu, H. (1990) "PET and methionine in assessment of response in non-Hodgkin lymphoma". LafiCei I. 1188.
   Google Scholar
• Huh, C.K., Glaspy, ),, Rosen, P., er at., (1997) "Whole-body FDO-PET imaging for staging of Hodgkin's disease and lymphoma", J. Noel. Med. 38, 343–348.
   Google Scholar
• Stompe. K.D.M.. Urbiaelli. M., Steinert. H.C., ri a. (1998) "Whole-body positron emission tomography using fluomdeoxygl u-cuse for staging of lymphoma: effectiveness and comparison with computed tomography". Ear J. Nucl. Med. 25, 721–728.
   PubMedGoogle Scholar
• Moog, E. Bangerter, M., Diederichs„ C.0,. at at.. (1998) "Extranodal malignant lymphoma: detection with FDG PET versus CT". Radiology 206, 475–481.
   PubMed Web of Science ®Google Scholar
• Bangerter, M.. Moog, F.. Bachmann. R-.. a at., (1998) "Whole-body l'Fl fluoro-2-deoxy-n-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease", Ann. Alcor. 9, 1117–1122.
   Google Scholar
• Carr. R. Barrington, S.F.. Madan, B., et at. (1998) "Detection of lymphoma in bone marrow by whole-body positron emission tomography". Blood 91. 3340 3346.
   PubMed Web of Science ®Google Scholar
• Romer, W.. Hanatiske. A.R.. Ziegler. S.. a at.. (1098) "Positron emission tomography in non-Hodgkin's lymphoma; assessment of chemotherapy with fluorodeoxyglucose", mood 91. 4464–4471.
   Google Scholar
• Ironzerke, J,, Guhlmann. A.. Moog, F.. et at. (1999) -Role of attenuation correction for luorine-18 fluorodcoxyglucose positron emission tomography in the primary gaging of malignant lymphoma". Ear. J. Nua Med. 26. 31–38.
   Google Scholar
• Jerusalem. a. %thud, V.. Najjar. F.. et at, (1999) "Whole-body "F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma". Nan. Med. Commun. 20. 13–20.
   Google Scholar
• Spaepen, K., Stroumbants, S., Dupont. P., a at.. (2001) "Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose (I " Fi FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is (1"Fl FDG)-PET a valid alternative to conventional diagnostic methods?". J. Cin. °neat 19, 414–419.
   Web of Science ®Google Scholar
• Mild-med. N.G.. Timothy, A.R., Hain, S.F. and O'Doherty. MJ. (2000) "18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas". Ann. Oncot 11. 5147–5150.
   Web of Science ®Google Scholar
• Mainolfi, C.. Maurea. S. and Verrella. P. (1998) "Positron emission tomography with Iluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinic°. radiologic assessment", Radial. Med. 95, 98–104.
   Google Scholar
• Jerusalem. G.. Regain. Y. and Fassotte. M.F. (1999) "Whole-body positron omission tomography using 16F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging". Bland 94. 429 433.
   Google Scholar
• Cremerius. U., Fabry, U., Knoll. U.. et at, (1999) "Clinical value of FOG pET for therapy monitoring of malignant lymphoma-results of a retrospective study in 72 pane nts", Nriklearinedizin 38.24–30.
   PubMedGoogle Scholar
• Magagnofi, M., Chierichetti. F., el at. (1999) "Therole of positron emission tomography (PET) in the management of lymphoma patients". Ann. Onto!. 10. 1181–1184.
   Google Scholar
• Kostakoglu. L. and Goldsmith, SJ. (2000) "Fluorine-13 flurodeos yghicose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?", Ear J. Nucl, Med, 27, 1564-157B.
   Google Scholar
• Harris. NI_ Jaffe, ES., Stein. H.. ci at., (1994) "A revised European American classification of lymphoid neoplasms: a proposal from the international lymphoma study group", Blood 84. 1161 1392.
   Web of Science ®Google Scholar
• Oke n, M., Creech, R. and Tonmey. D. (1982) "Toxicity and response criteria of the eastern cooperative oncology group". Am, J. Clio. Oncol. 5, 60–655.
   Google Scholar
• Bonadonna, O.. Zucali, R., De Lena. P.. et at. (1977) "Combinared chemotherapy (MOPP or ABVD)-radiothcrapy approach in advanced Hodgkin's disease". Cancer Trear. Rep. 61. 769–777.
   PubMedGoogle Scholar
• Klink). P. and Connors. J.M. (1985) "MACOP-13 chemotherapy for the treatment of diffuse large-cell lymphoma", Ann. ;mem Med. 102. 596–602.
   Web of Science ®Google Scholar
• Zin mai. EL.. Storti, S.. Zaccaria, A.. el at. (1999) "Elderly aggressive-histology non-Hodgkin's lymphoma: tirst-line VNCOP-B regimen experience on 350 patients". Blood 94. 33–38.
   Google Scholar
• Kaplan. E.S. and Meier. P. (1958) "Nonpararnetric estimation from incomplete observations", J. Am. Star. Assoc. 53, 457-'18 I.
   Google Scholar
• Mantel, H. and Haenzel. W. (1919) 'Statistical aspects of the analysis of data from retrospective studies of diseases".NallCancer Mai 22, 719–748.
   Google Scholar
• Candlos.G.P. (1989) "Residual disease of fibrosis". Onto!. J. Club. 16–17.
   Google Scholar
• Sutbone. A.. Longo, Di., DeVita, V.T.. et at. (1993) "Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: significances and management", J. Clin. OncoL 6, 1332–1837.
   Google Scholar